The concept of viruses to treat human malignancy is not new. In the mid 1890's William B. Coley, a New York surgeon, noted that infections could result in an impressive tumor response. Not much later, Louis Pasteur observed that patients with cervical cancer showed regression after being vaccinated with an attenuated rabies virus. By the mid-twentieth century scientists understood that some viruses were able to invade almost any cell in the body and kill it. However, it would not…Continue
Added by Editorial Team on October 28, 2015 at 6:30pm — No Comments
By John Leifer - Contributing editor
Providers of cancer treatment and therapeutics have learned to carefully hone their rhetoric so that it conveys a socially appropriate sense of altruism. Yet, beneath this thin veneer exists a motivation every bit as powerful as saving lives – reaping billions of dollars in profit. That’s what’s at stake in the…Continue
Added by Editorial Team on October 16, 2015 at 10:30am — No Comments
Earlier today Incyte Corporation and Merck & Co., Inc , known as MSD outside the United States and Canada, announced that they have agreed to expand the ongoing clinical trial collaboration to include a Phase III study evaluating the combination of epacadostat, Incyte’s investigational selective Indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor, with pembrolizumab (Keytruda®)*, Merck’s anti-PD-1 therapy, as first-line treatment for patients with advanced or metastatic melanoma.
Added by Editorial Team on October 13, 2015 at 9:30am — No Comments